Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths in the U.S., responsible for about 160,000 deaths a year—more than colon, breast & prostate cancer combined. Patients with late-stage non-small cell lung cancer (NSCLC), a cancer most often caused by cigarette smoking, have many options when considering therapies to extend survival. However, as reported by numerous scientific publications over the last few years, only approximately 50% of patients with advanced, non-squamous NSCLC are candidates for targeted chemotherapy (tyrosine kinase inhibitor) drugs or immunotherapy. The remaining 45,000 men and women with late-stage disease most often are treated with chemotherapy if they are not eligible for those other therapies. With a median survival of less than 10 months while on approved chemotherapy regimens, there is a significant unmet need in these patients with late-stage disease to slow progression and improve overall survival.